Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Generic Oncology Drugs Market Through 2029?

The market size for generic oncology drugs has seen robust growth in past years. The market, which was valued at $27.24 billion in 2024, is projected to rise to $28.75 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.5%. This growth in the historical period can be tied to factors such as the expiration of patents, containment of healthcare costs, rising cancer incidence, health insurance coverage, and prescribing practices of physicians.

The market size for generic oncology medications is predicted to witness substantial increase in the coming years. It is expected to expand to “$37.08 billion in 2029 with a compound annual growth rate (CAGR) of 6.6%”. The growth during this period is likely due to factors such as approval of biosimilars, heightened competition, the rise in telemedicine and remote health care, personalized treatment approach, and pricing pressure. Further, the forecast period will see trends like augmented pharmacovigilance, refined regulatory processes, focus on combination therapy, precise generic oncology drugs, and broader market access.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12174&type=smp

What Market Forces Are Driving The Generic Oncology Drugs Sector In 2025 And Beyond?

The anticipated surge in cancer patients is predicted to accelerate the development of the generic oncology drugs market. Cancer is characterised by the unchecked growth of cells that affect different body organs and result in significant global morbidity and mortality. The presence of affordable generic oncology drugs is vital in cancer treatment as it expands access to necessary treatments, stimulates market competition, and lowers healthcare expenses. For example, in January 2022, the National Cancer Institute (NCI), a U.S government agency, reported that around 5.4% of the population, or 18.1 million people, in the United States were cancer survivors. Furthermore, 623,405 individuals were dealing with metastatic cancer of the breast, prostate, lung, colorectal, bladder, or metastatic melanoma in 2022, with an expectation to increase to 693,452 by 2025. Therefore, the dramatic increase in cancer patients is fuelling the expansion of the generic oncology drugs market.

The generic oncology drugs market covered in this report is segmented –

1) By Molecule Type: Large Molecule, Small Molecule

2) By Route Of Administration: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Managed Care Institutions

Subsegments:

1) By Large Molecule: Monoclonal Antibodies, Biologics, Biosimilars

2) By Small Molecule: Chemotherapeutics, Targeted Therapy Agents, Hormonal Therapy Drugs

What Notable Trends Are Shaping The Direction Of The Generic Oncology Drugs Market?

The trend of innovative formulations is on the rise in the generic oncology drugs market. To secure their stance in the market and increase patient adherence, major corporations in the arena are concentrating on creating new drug delivery mechanisms, altered-release formulations, and differing dosage forms. A case in point is the launch of Palborest, a generic Palbociclib tablet for advanced breast cancer treatment, by MSN Laboratories Private Limited, an India-based company specializing in generic drugs, in January 2023. This generic breast cancer medication offers an affordable alternative to the original tablet but still retains bioequivalence. The tablet form has a distinctive benefit over capsules as it allows for administration with or without the need for food, along with proton pump inhibitors or antacids. Additionally, the absence of lactose and gelatin in the tablet formulation augments the efficacy of the drug.

Which Firms Are Considered Leaders In The Generic Oncology Drugs Market Space?

Major companies operating in the generic oncology drugs market include Pfizer Inc., AbbVie, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Fresenius Kabi AG, GlaxoSmithKline PLC, Eli Lilly and Company, Merck & Co. Inc., Baxter International Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Hikma Pharmaceuticals, Endo Pharmaceuticals Inc., Aspen Pharmacare Holdings Limited, Lupin Limited, Towa Pharmaceutical Co Ltd, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Accord Healthcare

https://www.thebusinessresearchcompany.com/report/generic-oncology-drugs-global-market-report

What Role Do Regional Policies And Investments Play In Generic Oncology Drugs Market Expansion?

North America was the largest region in the generic oncology drugs market in 2024. The regions covered in the generic oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12174&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model